enVVeno Medical (NVNO) AI Stock Analysis

• Market Cap: $80.65M
• Dividend Yield: N/A
• Average Volume (3M): 170.25K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: N/A
• EPS Growth: 15.60%
• Country: US
• Employees: 37
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Devices
• EPS (TTM): -0.33
• Shares Outstanding: 19,247,140
• 10 Day Avg. Volume: 206,320
• 30 Day Avg. Volume: 170,246
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.58
• Enterprise Value/Revenue: 57.81
• Enterprise Value/Gross Profit: 1.88K
• Enterprise Value/Ebitda: -1.95
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 58 Neutral
• Price Target: ―

enVVeno Medical's overall stock score is influenced by its robust technical performance, which is somewhat overshadowed by challenging financial metrics. The company faces significant profitability issues, as reflected by its negative income and cash flow figures, despite having a stable balance sheet. While technical indicators show strong upward momentum, valuation concerns due to a negative P/E ratio and lack of dividends weigh on the score.

enVVeno Medical Business Overview & Revenue Model

Company Description

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

How the Company Makes Money

enVVeno Medical makes money by developing, manufacturing, and selling medical devices designed to treat venous diseases. The company's primary revenue stream comes from the sales of its proprietary products aimed at improving venous valve function, particularly for patients with chronic venous insufficiency. Key factors contributing to its earnings include product sales to healthcare providers, partnerships with medical institutions for clinical trials and product distribution, and potentially licensing or royalty agreements related to its patented technologies. The company's ability to generate revenue is closely tied to the successful commercialization of its products and the establishment of strategic partnerships within the healthcare industry.

enVVeno Medical Financial Statement Overview

Summary

enVVeno Medical faces significant financial challenges, marked by substantial losses and negative cash flows. The income statement shows severe profitability issues with highly negative margins. The balance sheet, however, indicates strong financial stability due to low leverage and high equity. Cash flow analysis reveals insufficient cash flow generation from operations, necessitating strategic initiatives for improvement.

Income Statement

enVVeno Medical's income statement reveals a challenging financial position. The company has only recently generated revenue in the TTM period, with a gross profit margin of 17.37%. However, net income remains significantly negative, resulting in a net profit margin of -2626.72%. The EBIT and EBITDA margins also indicate substantial losses, at -2866.26% and -2819.95% respectively. These figures highlight ongoing operational challenges and a need for strategic shifts to improve profitability.

Balance Sheet

The balance sheet of enVVeno Medical shows a strong equity position with a low debt-to-equity ratio of 0.03, indicating minimal leverage and financial risk. The equity ratio stands at 94.40%, underlining substantial equity financing. However, the company's return on equity is negative at -55.68%, reflecting the impact of net losses. Despite the robust equity standing, profitability remains a significant concern.

Cash Flow

The cash flow analysis for enVVeno Medical reflects negative operating and free cash flows, with a free cash flow growth rate of -2.73% from the previous year. The operating cash flow to net income ratio is 0.81 for the TTM period, indicating that cash flows are not sufficient to cover net losses. While financing activities have contributed positively, the company must improve cash flow generation from operations to sustain long-term viability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	812.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	25.00K	-528.00K	-546.00K	-525.00K	-452.91K	-383.97K
EBITDA	-24.01M	-21.29M	-25.02M	-24.14M	-16.75M	-8.75M
Net Income	-23.07M	-21.82M	-23.52M	-24.67M	-16.53M	-9.14M
Balance Sheet
Total Assets	36.58M	44.95M	48.63M	41.66M	57.70M	10.54M
Cash, Cash Equivalents and Short-Term Investments	35.14M	43.15M	46.41M	39.04M	54.73M	9.33M
Total Debt	882.00K	1.06M	1.40M	1.72M	2.01M	880.65K
Total Liabilities	3.52M	2.79M	2.44M	2.93M	3.29M	3.44M
Stockholders Equity	33.06M	42.16M	46.20M	38.73M	54.40M	7.10M
Cash Flow
Free Cash Flow	-18.35M	-16.88M	-18.89M	-15.73M	-12.21M	-7.86M
Operating Cash Flow	-18.46M	-16.84M	-18.86M	-15.62M	-11.85M	-7.68M
Investing Cash Flow	3.19M	1.33M	-7.87M	-34.55M	-367.89K	-180.29K
Financing Cash Flow	13.59M	13.64M	25.79M	0.00	57.61M	15.07M

enVVeno Medical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.97
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVNO, the sentiment is Negative. The current price of 0.97 is below the 20-day moving average (MA) of 4.39, below the 50-day MA of 4.36, and below the 200-day MA of 3.46, indicating a bearish trend. The MACD of -0.49 indicates Positive momentum. The RSI at 18.05 is Positive, neither overbought nor oversold. The STOCH value of 9.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NVNO.

enVVeno Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVNO	58 Neutral	$80.65M	―	-64.55%	―	―	15.60%
Sector *	51 Neutral	$7.77B	-0.12	-39.78%	2.21%	22.68%	-1.42%
ECOR	51 Neutral	$37.69M	―	-210.58%	―	30.16%	22.51%
APYX	44 Neutral	$74.50M	―	-156.90%	―	-5.14%	44.86%
MODD	―	$38.69M	―	-215.41%	―	―	―
TELA	48 Neutral	$68.93M	―	-676.41%	―	16.34%	34.86%
RBOT	39 Underperform	$38.15M	―	-125.63%	―	―	6.48%